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Abstract 
 
Oncostatin M (OSM) is an interleukin-6 (IL-6)-family cytokine that has been implicated
 
in a 
number of biological processes including inflammation, hematopoiesis, immune responses, 
development, and bone homeostasis.  Recent evidence suggests that OSM may promote breast 
tumor invasion and metastasis.  We investigated the role of OSM in the formation of bone 
metastases in vivo using the 4T1.2 mouse mammary tumor model, in which OSM expression 
was knocked down using shRNA (4T1.2-OSM).  4T1.2-OSM cells were injected 
orthotopically into Balb/c mice resulting in a greater than 97% decrease in spontaneous 
metastasis to bone compared to control cells.  Intratibial injection of these same 4T1.2-OSM 
cells also dramatically reduced the osteolytic destruction of trabecular bone volume compared 
to control cells.  Furthermore, in a tumor resection model, mice bearing 4T1.2-OSM tumors 
showed an increase in survival by a median of 10 days.  To investigate the specific cellular 
mechanisms important for OSM-induced osteolytic metastasis to bone, an in vitro model was 
developed using the RAW 264.7 pre-osteoclast cell line co-cultured with 4T1.2 mouse 
mammary tumor cells.  Treatment of co-cultures with OSM resulted in a 3-fold induction of 
osteoclastogenesis using the TRAP assay.  We identified several tumor cell-induced factors 
including vascular endothelial growth factor (VEGF), IL-6, and a previously uncharacterized 
OSM-regulated bone metastasis factor, amphiregulin (AREG), which increased osteoclast 
differentiation by 4.5-fold.  In addition, pre-treatment of co-cultures with an anti-AREG 
neutralizing antibody completely reversed OSM-induced osteoclastogenesis.  Our results 
suggest that one mechanism for OSM-induced osteoclast differentiation is via an AREG 
autocrine loop resulting in decreased osteoprotegrin (OPG) secretion by the 4T1.2 cells.  These 
data provide evidence that OSM might be an important therapeutic target for the prevention of 
breast cancer metastasis to bone.  
 
Keywords:  oncostatin M, OSM, bone metastasis, breast cancer, osteolysis, osteoclastogenesis 
 
Introduction 
 
Breast cancer is the most commonly diagnosed cancer in women worldwide, with approximately 200,000 new cases 
being reported each year in the United States alone (1).  Seventy percent of breast cancer patients with advanced 
disease have bone metastasis.  Though not a direct cause of death, these metastases often lead to weakening of 
weight-bearing bones due to osteolytic lesions, resulting in severe pain, pathologic fractures, and hypercalcemia (2).  
While mechanisms of breast cancer progression have been researched extensively, metastasis specifically to osseous 
tissue is understudied, and therefore, the role of inflammatory factors in this process is not well understood.  Recent 
data from human serum samples indicate that the promotion of metastasis to bone may be caused by inflammatory 
cytokines in the interleukin-6 (IL-6) family (3).  
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Oncostatin M (OSM) is a pleiotropic IL-6 family cytokine important in inflammation and other cellular processes 
such as development, hematopoiesis, liver function, neurogenesis, and bone homeostasis (4).  OSM activates the 
JAK/STAT, MAPK, and PI3K/AKT pathways via binding its receptors, OSM receptor beta (OSMR or leukemia 
inhibitory factor receptor beta (LIFR dimerized with a common gp130 subunit (5-8). During oncogenesis, OSM 
often acts as an anti-proliferative factor for multiple types of cancers including multiple myeloma, lung cancer, and 
breast cancer (9, 10).  Paradoxically, OSM has also been shown to increase the proliferation of prostate and ovarian 
cancer cells, although this discrepancy is not well defined (11, 12).  Though OSM may promote or inhibit tumor cell 
proliferation, recent research suggests a contributing role for this cytokine in metastasis (13-16). 
 
In breast cancer, OSM has been shown by our group and others to i) increase the transition of various cancer cell 
types from an epithelial to a mesenchymal phenotype (EMT) (15), ii) promote breast tumor cell-substrate 
detachment and invasion in vitro (13, 14), iii) upregulate proteases such as matrix metalloproteinases (MMPs) and 
cathepsins that degrade the local extracellular matrix (unpublished results; (14, 16)), and iv) induce proangiogenic 
factors such as vascular endothelial growth factor (VEGF) (17, 18).  In human tissue, OSM is expressed at low 
levels in normal mammary epithelial cells and at higher levels in ductal carcinoma in situ and invasive breast 
carcinoma (unpublished results; (19)).  High levels of OSM are also found in the breast tumor microenvironment in 
both tumor-associated macrophages and neutrophils that express and release OSM in response to breast carcinoma 
cells in vitro (20-22). These studies suggest a role for both autocrine and paracrine signaling by OSM in tumor cell 
detachment and invasion during early stages of the metastatic cascade.  The role of OSM in bone colonization and 
osteolysis has not been addressed previously, but OSM, IL-6, and other gp130-related factors have been shown to 
regulate normal bone homoeostasis (23-26). 
 
Bone homeostasis is maintained via a constant balance between mineralized bone formation and bone resorption.  
These processes are mediated primarily by the osteoblasts that synthesize mineralized bone and the osteoclasts that 
resorb bone.  The role of OSM in maintaining normal bone homeostasis has been documented in several in vitro and 
in vivo models including OSM and OSMR knockout mice that show reduced osteoclast differentiation and activity 
(27-30).  There is also evidence that OSM induces mineralization in mouse osteoblast cells (31); however, during 
disease states such as osteoarthritis and osteolytic bone metastasis, the balance of OSM and other IL-6/gp130 
cytokines has been shown to be severely disrupted, often leading to bone degradation (25).  
 
Breast cancer-derived bone metastasis leads to the dysregulation of IL-6, IL-11, and various growth factors such as 
receptor activator of NFB (RANKL), macrophage-colony stimulating factor (MCSF), and VEGF by different cell 
types including osteoblasts, stromal cells, and immune cells (4, 23, 32, 33).  These factors promote osteoclast 
differentiation and activity, leading to increased bone resorption and compromised structural bone integrity. 
Currently, there are no published investigations addressing the in vivo role of OSM in breast cancer metastasis to 
bone.  
 
To investigate the effect of OSM on bone metastasis, we utilized the 4T1.2 syngeneic mouse model of breast cancer.  
The 4T1.2 cell line (34) is a subclone of 4T1 cells that were originally derived from a spontaneous mammary tumor 
in a Balb/c/C3H mouse (35).  When injected orthotopically, 4T1.2 cells metastasize to bone as well as lung, adrenal 
glands, and lymph nodes (34): a metastatic pattern similar to that seen in breast cancer patients.  In this study, we 
generated modified cell lines by knocking down expression of OSM (4T1.2-OSM) and show that a lack of OSM 
expression is sufficient to inhibit metastasis to bone from the primary mammary tumor as well as increase survival.  
Additionally, osteolysis observed after intratibial injection of 4T1.2-OSM cells is significantly reduced in mice 
compared to control cells.  By treating co-cultures of 4T1.2 and RAW 264.7 cells (peripheral blood mononuclear 
cells (PBMCs), a cellular model of pre-osteoclasts) with OSM, we show that OSM-induced secretion of IL-6, 
VEGF, and amphiregulin (AREG) promote osteoclastogenesis.  Altogether, these findings indicate that targeting 
OSM expression and signaling provide a novel therapeutic approach for treatment of metastatic breast cancer. 
 
Results 
 
OSM increases the invasive potential of mammary tumor cells in vitro 
 
Previous results from our group indicate that OSM may play an important role in early stages of metastasis (13, 14, 
20).  Mouse mammary tumor 4T1.2 cells were characterized in vitro to establish them as a credible model for 
studying OSM signaling in vivo.   First, we evaluated OSM and OSMR expression levels by comparing the highly 
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metastatic 4T1.2 mammary tumor cells to a non-bone metastatic cell line, 66c14, also derived from the same 
Balb/c/C3H mammary tumor.  4T1.2 cells secreted 2-fold more OSM and expressed 2.5-fold more OSM receptor 
(OSMR, as compared to 66c14 cells (Fig. 1A and B).  The treatment of 4T1.2 cells with OSM (25 ng/ml) resulted 
in a 20% reduction in adherent cells by day 10 (Fig. 1C, left) and a 60-fold induction of viable tumor cell 
detachment by day 8 (Fig. 1C, right).  The decrease in adherent cell number could be explained by the increase in 
cell detachment or effects on proliferation. 
 
In addition, we observed an approximate 50% increase in 4T1.2 cell invasive potential after a 24 hour exposure to 
OSM using a Matrigel invasion assay (Fig. 1D).  The above experiments confirmed that OSM signaling is intact in 
4T1.2 cells and that these cells can be used to study the contribution of OSM to metastasis to bone in vivo. 
 
OSM is necessary for mammary tumor metastasis to bone 
 
To examine whether OSM is required for mammary tumor metastasis to bone, we undertook stable knockdown of 
OSM expression (Fig. 2A; left panel).  Three independent OSM shRNA sequences were cloned into the pSilencer4.1 
vector, transfected into 4T1.2 mouse mammary tumor cells, and two clonal cell populations showed reduced OSM 
expression.  Of the two clones, 4T1.2-OSM2 cells secreted the lowest levels of OSM (72% less OSM; 14.9  2.3 
pg/ml) by ELISA compared to 4T1.2-LacZ control cells (53.1  8.8 pg/ml; Fig. 2A), and 4T1.2-OSM1 cells secreted 
30% less OSM (37.0  5.9 pg/ml) (Fig. 2A).  OSM mRNA expression levels were confirmed by semi-quantitative 
RT-PCR (Fig. 2A, inset).  To test the effects of OSM on mammary tumor metastasis in vivo, control 4T1.2-LacZ, 
4T1.2-OSM1, and 4T1.2-OSM2 cells were injected orthotopically into the mammary fat pads of Balb/c mice.  As 
OSM has been shown to have anti-proliferative effects on breast cancer cells in vitro (9, 10), we hypothesized that 
low levels of OSM should result in increased tumor growth in vivo.  Injection of 4T1.2-OSM2 cells, which displayed 
the largest decrease in tumor cell-secreted OSM, led to a significant increase in average tumor growth (1,628 mm
3
 
for 4T1.2-OSM2 cells at day 30; Fig. 2B) compared to control 4T1.2-LacZ cells (860 mm
3
 at day 30; Fig. 2B) and 
parental 4T1.2 cells (870 mm
3 
at day 30; data not shown).  Injection of 4T1.2-OSM1 cells, which displayed a 
modest decrease in tumor cell-secreted OSM, resulted in tumor growth similar to control cells (861 mm
3
 at day 30; 
Fig. 2B).   
 
Metastasis to bone in mice injected with control 4T1.2-LacZ, 4T1.2-OSM1, and 4T1.2-OSM2 cells was quantified 
by qPCR, which measures the amount of vector DNA contained in all three cell types. Mean bone metastatic burden 
in spine was significantly lower in mice that received 4T1.2-OSM1 or 4T1.2-OSM2 cells, compared to 4T1.2-LacZ 
control cells (Fig. 2C).  Histological evaluation of vertebrae by H & E staining revealed the presence of metastatic 
tumor cells in the bone marrow of mice injected with 4T1.2-LacZ control cells but not in the bone marrow of mice 
injected with 4T1.2-OSM2 cells (Fig. 2D).  After careful inspection, a small intraosseous metastasis was identified 
in vertebrae from a mouse injected with 4T1.2-OSM1 cells, explainable by the fact that these cells did not 
demonstrate as robust an OSM expression knockdown as the 4T1.2-OSM2 cells.  Overall, these results suggest that 
tumor cell-expressed OSM is necessary for mammary tumor metastasis to bone. 
 
In addition to the increased tumor growth and decreased metastasis to bone observed in mice injected with 4T1.2-
OSM2 cells in vivo, these cells also demonstrate decreased invasive potential in vitro. Specifically, 4T1.2-OSM2 
cells displayed an increase in adherent cell number over time (data not shown), a decrease in viable cell detachment 
(Supplemental Fig 1A), and a decrease in invasive potential (Supplemental Fig 1B) compared to 4T1.2-LacZ control 
cells. These results demonstrate that 4T1.2-OSM2 cells display a reduced invasiveness in vitro and provide an 
appropriate model for subsequent in vivo experiments. 
 
OSM promotes mammary tumor cell-mediated osteolysis in vivo 
 
4T1.2-OSM2 and control cells were injected into the tibia of Balb/c mice.  Legs excised four weeks after injection of 
control 4T1.2-LacZ cells showed significant osteolysis in the proximal end of the tibia, as analyzed by Micro CT.  
The same region in mice injected with 4T1.2-OSM2 cells showed less osteolysis, more closely resembling PBS-
injected animals (Fig. 3A); however, a mixed osteolytic/osteoblastic phenotype was seen.  Analysis of trabecular 
bone revealed extensive osteolysis due to 4T1.2-LacZ cells, prohibiting 3D reconstruction of the region of interest 
(ROI) in all but one animal (Fig. 3B, top and Supplemental Fig. 2A).  Mice injected with 4T1.2-OSM2 cells 
displayed a trabecular bone morphology more similar to that of PBS-injected mice (Fig. 3C, top and Supplemental 
Fig. 2A).  A similar pattern was observed in the cortical bone (Fig. 3B, bottom and Supplemental Fig. 2B). 
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Quantitative analysis of trabecular and cortical bone was performed using ROIs (50 x 10 m slices).  Mice injected 
with 4T1.2-OSM2 cells displayed a dramatically greater total trabecular bone volume and trabecular thickness when 
compared to control 4T1.2-LacZ cells (Fig. 3C).   Both cortical bone volume/total volume and cortical bone mineral 
density were significantly higher in 4T1.2-OSM2 cell-injected mice as compared to mice injected with control cells 
(Fig. 3C).  Overall, these quantitative results indicate that OSM expression is important for osteolytic activity of 
4T1.2 cells in the bone microenvironment. 
 
Lack of mammary tumor cell-derived OSM increases survival in vivo 
 
To determine the influence of decreased OSM expression on bone metastasis independent of its effects on primary 
tumor growth, we utilized a tumor resection model.  Orthotopic mammary fat pad injections were performed using 
control 4T1.2-LacZ and 4T1.2-OSM2 cells, primary tumors were resected at day 14 (Fig. 4A), and mice were 
monitored until endpoint criteria were met (see Materials and Methods).   The survival time for mice that received 
4T1.2-OSM2 cell injections significantly increased by a mean of 10 days and a maximum of 42 days compared to 
control 4T1.2-LacZ cells (Fig. 4B).  In addition, mice injected with 4T1.2-OSM2 cells had no detectable metastases 
in the spines, as analyzed by qPCR, whereas all of the mice injected with 4T1.2-LacZ cells demonstrated high levels 
of metastases in the spine (Fig. 4C).  Lung metastases were detectable in both the 4T1.2-LacZ and 4T1.2-OSM2 
groups of mice at the time of sacrifice; however, the time for maximum metastasis to the lungs was significantly 
delayed in the 4T1.2-OSM2 injected group (data not shown).  These results indicate that following primary tumor 
resection, decreased OSM expression in mammary tumor cells delayed bone metastasis and increased the animal 
survival rate. 
 
OSM induces tumor cell-mediated osteoclastogenesis 
 
To identify the mechanism by which mammary tumor cell-derived OSM causes osteolysis, an in vitro model of 
osteoclastogenesis mimicking PBMC-derived osteoclasts was employed using RAW 264.7 mouse monocytic cells 
co-cultured with 4T1.2 cells.  The capacity of each cell type to respond to OSM and other OSM-related factors was 
analyzed by semi-quantitative RT-PCR.  Both the RAW 264.7 cells, which are able to undergo osteoclast 
differentiation, and the 4T1.2 mouse mammary tumor cells expressed the gp130 subunit necessary for all IL-6 
family receptors (Fig. 5A).  4T1.2 cells expressed OSMR, LIFR, and IL-6R, while RAW 264.7 cells expressed 
IL-6R and barely detectable levels of LIFR (Fig. 5A).  Therefore, in our in vitro model of osteoclastogenesis, we 
predicted that the 4T1.2 cells should respond to OSM, LIF, and IL-6 and that the RAW 264.7 cells should not 
respond to OSM.   
 
The ability of 4T1.2 cells to induce osteoclastogenesis in response to OSM was assessed. A 7.5-fold increase in 
TRAP-positive (TRAP+) cells, a marker of osteoclast differentiation, was observed in OSM-treated RAW 264.7 and 
4T1.2 co-cultures compared to untreated co-cultures in the presence of 5ng/mL MCSF and 10 ng RANKL (Fig. 5B).  
To demonstrate the importance of OSM-mediated secreted factors from 4T1.2 cells, conditioned medium (CM) was 
collected from 4T1.2 cells treated with or without OSM and applied to RAW 264.7 cells.  An approximate 3-fold 
increase in TRAP+ osteoclasts was observed in RAW 264.7 cells cultured with CM (+OSM) compared to CM (-
OSM) (Fig. 5B).  No significant difference in the level of osteoclastogenesis was observed when RAW 264.7 cells 
alone were treated with OSM (Fig. 5B.)   
 
Mammary tumor cells secrete pro-osteoclastogenic factors in response to OSM 
 
To identify which 4T1.2 cell-secreted pro-osteoclastogenic factors were increased in response to OSM, ELISA and 
Western blot analyses were performed.  No difference in the levels of 4T1.2 cell-derived RANKL, MCSF, 
transforming growth factor beta (TGF), or tumor necrosis factor alpha (TNF) was observed after treatment with 
OSM (Supplemental Table 2).  However, levels of IL-6 and VEGF, whose receptors are both present on RAW 264.7 
cells (Fig. 5A), were significantly increased in response to OSM (Fig. 5C and D).  4T1.2 cells alone, as well as 
RAW 264.7 and 4T1.2 cell co-cultures showed a 3- to 4-fold increase in secreted IL-6 levels when treated with 
OSM (Fig. 5C).  RAW 264.7 cells alone did not show a significant increase in IL-6 in response to OSM (Fig. 5C).  
VEGF secretion by 4T1.2 cells was increased 2-fold following treatment with OSM verses untreated cells (Fig. 5D).  
Secreted VEGF levels increased 7-fold in treated co-cultures compared to untreated 4T1.2 cells, suggesting that in 
addition to OSM treatment, a direct interaction between the two cell types may cause an increase in VEGF.  
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OSM-induced amphiregulin in mammary tumor cells increases osteoclastogenesis 
 
Amphiregulin (AREG), a member of the epidermal growth factor (EGF) family and previously unknown to be 
induced by OSM, was identified by proteome array analysis (R&D Systems) of conditioned medium from 4T1.2 
cells treated with OSM (see Supplemental Materials and Methods).  A more than 2-fold increase in secreted AREG 
was verified by ELISA in CM collected from OSM-treated 4T1.2 cells as compared to untreated cells (Fig. 6A, left).  
Co-culturing RAW 264.7 cells with 4T1.2 cells had no effect on OSM-induced AREG secretion levels, and RAW 
264.7 cells alone did not increase AREG secretion in response to OSM (Fig. 6A, left).  To determine whether AREG 
plays a direct role in osteoclastogenesis in our in vitro model, recombinant AREG (50 ng/ml) was added to co-
cultures of RAW 264.7 and 4T1.2 cells in the presence of 5 ng/mL MCSF and 10 ng RANKL.  AREG 
supplementation increased the number of TRAP+ osteoclasts by 2-fold in these co-cultures, and addition of OSM 
with AREG further increased the number of TRAP+ osteoclasts by nearly 9-fold compared to untreated controls 
(Fig. 6A, right).  AREG showed a minimal effect on osteoclastogenesis in cultures of RAW 264.7 cells alone (Fig. 
6A, right).  Inhibition of AREG signaling using a neutralizing antibody in RAW 264.7 and 4T1.2 cell co-cultures 
resulted in a near complete suppression of OSM-mediated osteoclastogenesis (Fig. 6B, left).   No significant effect 
was seen in RAW 264.7 cultures (Fig. 6B, left).  A combination of anti-IL-6, anti-VEGF, and anti-AREG antibodies 
did not significantly reduce osteoclastogenesis beyond co-cultures treated with anti-AREG only (Fig. 6B, right).  
Anti-IL-6 or anti-VEGF antibodies alone had less effect on inhibition of OSM-induced osteoclastogenesis in co-
cultures than anti-AREG (Fig. 6B, right).  Thus, OSM-induced AREG appears to be a key player in mammary tumor 
cell-induced osteoclastogenesis in vitro. 
 
OSM inhibits osteoprotegrin expression in tumor cells  
 
Osteoprotegrin (OPG), the decoy receptor for RANKL, is an important endogenous inhibitor of osteoclastogenesis.  
Preliminary data from our group have shown expression of OPG is decreased by RT-PCR in a panel of human breast 
cancer cells treated with OSM (data not shown).  Therefore, we investigated the effect of OSM on OPG expression 
by 4T1.2 mouse mammary tumor cells by both RT-PCR and ELISA.  OSM treatment of 4T1.2 cells resulted in a 
40% reduction in secreted OPG levels by ELISA (Fig. 6C; left) and an 80% reduction in mRNA expression by RT-
PCR (Fig. 6C; right).  Interestingly, the addition of recombinant AREG (25 ng/ml) also resulted in an 80% decrease 
in OPG expression (Fig. 6C; right), suggesting that OSM-mediated osteoclastogenesis may act through AREG 
suppression of OPG. 
 
Discussion 
 
This study provides evidence that tumor cell-secreted OSM promotes osteolytic breast cancer metastasis to bone.  
Our data indicate that OSM is important in late stages of the metastatic process but may also be necessary for earlier 
stages.  We show, specifically: i) OSM induces 4T1.2 mouse mammary tumor cell detachment and invasion in vitro; 
ii) mice orthtopically injected with 4T1.2 tumor cells with reduced OSM expression exhibit decreased bone 
metastases and increased survival; iii) intratibial injections of the above 4T1.2 cells in mice result in decreased 
osteolysis; and iv) a novel mechanism for OSM promoting tumor cell-secreted amphiregulin during osteoclast 
differentiation was identified.   
 
The syngeneic 4T1.2 mouse model is the only reliable model for spontaneous mammary tumor metastasis to bone 
currently available.  Intracardiac or intratibial injections of osteolytic human breast cancer cells into 
immunocompromised athymic mice to study the role of OSM in bone metastasis is problematic due to a lack of 
homology between human and mouse OSM signaling (36), as well as the need for intact immune function to 
adequately study the effect of an inflammatory cytokine on metastasis.  Using our 4T1.2-OSM2 orthotopic mouse 
model, we observed a dramatic decrease in bone metastasis despite increased tumor growth.  A dual role as an anti-
proliferative and yet pro-metastatic factor in breast cancer metastasis has been shown with other breast cancer cell 
secreted factors such as transforming growth factor beta (TGFβ).  TGFβ is not regulated by OSM in 4T1.2 cells 
(Supplemental Table 2) but is known to increase invasion and metastasis of breast tumors along with its tumor cell 
growth inhibitory effects (37). To date, this is the first study demonstrating an independent and yet similar role for 
OSM driving breast cancer metastasis to bone, despite inhibitory effects on primary tumor growth. 
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Bone is the most common site of metastatic disease in breast cancer patients (1),  although metastasis also occurs to 
lung, liver, adrenal glands, brain, kidney, spleen, heart, and lymph nodes.  Specific quantification of metastatic 
burden by qPCR was conducted for spine and lung only (Fig. 2C; data not shown) and both were significantly 
reduced in mice orthotopically injected with 4T1.2-OSM1 and 4T1.2-OSM2 cells.  By utilizing a tumor resection 
model, we were able to increase the time it took to reach overall maximum metastatic burden and identify other 
important metastatic sites modulated by OSM.  Upon dissection of these mice at maximum metastatic endpoint, sites 
with visual metastases, in addition to the spine, were lung, liver, and lymph nodes.  A reduction in the number of 
lung metastases or prolongation of the time to lung metastasis development may explain the significant increase in 
survival seen in mice that had resected primary tumors with reduced OSM expression.  Therefore, the lung was 
identified as another major metastatic site affected by OSM and is being investigated further.  Overall, OSM is 
likely critical for both late as well as early stages of metastasis, resulting in an increase in total metastatic burden.  
However, our data suggest a more significant role for OSM during later steps of the metastatic process, specifically 
in the bone microenvironment. 
 
4T1.2-OSM2 tumor cells injected directly into the bone microenvironment of the tibia revealed that tumoral OSM 
expression is critical for induction of osteolysis in both trabecular and cortical bone.  In general, 4T1.2-OSM2 cell-
injected mice showed a mixed osteolytic/osteoblastic phenotype, similar to what is seen in human metastatic breast 
cancer patients (38).  Previous studies analyzing intrafemoral injection of 4T1 cells (the parental cells for the 4T1.2 
subclone used in this manuscript) show only osteolytic activity by Micro CT (39).  This manuscript is the first study 
presenting Micro CT data from intratibial injections of the 4T1.2 subclone.  4T1.2 cells injected into the mouse tibia 
resulted in some osteoblast activity, although overall the osteolytic phenotype was predominant (see Supplemental 
Figure 2).  OSM has been shown previously to play a dual role in the normal bone microenvironment stimulating 
both bone resorption as well as bone formation.  Specifically, OSM has been shown to promote osteoclastogenesis 
and osteoclast activity by STAT3-induced RANKL expression in osteoblast/stromal cells (40) yet will stimulate 
osteogenesis in mesenchymal stem cells and mineralization in murine osteoblast cells (31, 40).  The role of OSM in 
osteoblastogenesis and mineralization in our breast cancer metastasis model is currently being conducted.  However, 
we have measured osteoclast activity in vitro using a synthetic bone resorption assay, and increased bone resorption 
was detected using a mixed population of mouse primary pre-osteoclasts and pre-osteoblasts cultured in CM from 
4T1.2 cells treated with OSM (data not shown).  Increased osteolysis in the animals injected with 4T1.2-LacZ cells 
compared to parental 4T1.2 cells was also noted (see Supplementary Figure 2).  siRNA/shRNA technology has been 
shown to cause generally unavoidable off-target effects related to immune system activation, as the siRNA 
machinery is physiologically associated with viral infections (41, 42) that can potentially lead to aberrant 
osteoclastogenesis and osteolysis.  Overall, our studies suggest that tumor cell-derived OSM leads to an increase in 
both osteoclast differentiation and activity that result in osteolytic bone lesions. 
 
Using an in vitro co-culture system of osteoclast differentiation, this work presents evidence for several OSM-
induced tumor secreted factors that could mediate the observed in vivo osteolysis.  The RAW 264.7 mouse 
monocytic cell line was chosen as a source of pre-osteoclast cells in our in vitro model of tumor cell/bone 
microenvironment interaction instead of bone marrow cells derived from Balb/c mice. This decision was based on 
recent studies suggesting that peripheral blood mononuclear cells (PBMCs) that include monocytes, are a major 
source of osteoclasts in pathologic osteolysis. PBMCs isolated from patients with bone metastases have been shown 
to undergo spontaneous osteoclastogenesis (43-45), while similar effects with bone marrow cells isolated from 
cancer patients have not been reported.  Furthermore, we were able to maximize OSM-induced effects on 
osteoclastogenesis in our co-culture system by the addition of very low levels of RANKL and MCSF to all the 
assays.  The low level of these key osteoclast-promoting factors resulted in the formation of predominantly 
mononuclear TRAP+ cells, which, nonetheless, had direct osteolytic activity (data not shown; (46)).  The significant 
increase in RAW 264.7 TRAP+
 
cells in OSM-treated co-cultures with 4T1.2 cells or conditioned media from 4T1.2 
cells treated with OSM was mediated in part by IL-6 and VEGF.  Both IL-6 and VEGF have been shown by our 
group and others to promote osteoclast differentiation and activity (47, 48), and VEGF expression has been detected 
in osteolytic bone metastases (49).  To identify novel OSM-induced factors, a proteome array analysis of 
conditioned medium from 4T1.2 cells treated with OSM was performed, and AREG was identified.  AREG is 
membrane-bound until cleaved by the protease ADAMTS1 (a disintegrin and metalloproteinase with 
thrombospondin motifs 1), expression of which was also induced by OSM in 4T1.2 cells (Supplemental Table 2).  
AREG has been associated with several mechanisms of breast cancer progression including tumor cell proliferation 
and the expression of proteases such as MMP2 and MMP9 (50) and is expressed at moderate to high levels in 
human infiltrating breast carcinoma (51, 52). 
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The role of AREG in breast cancer metastasis to bone has not been studied extensively. AREG has been shown to 
increase expression of parathyroid hormone related protein (PTHrP) from breast cancer cells in vitro, however in 
studies of human breast cancer bone metastases, it is unclear as to whether PTHrP expression drives the metastasis 
to bone or the bone microenvironment induces PTHrP expression (53).  In our 4T1.2 co-culture model, OSM-
induced AREG did not promote expression or secretion of PTHrP by RT-PCR and ELISA (Supplemental Table 2), 
but instead, resulted in decreased secretion of the decoy receptor for RANKL, osteoprotegrin (OPG).  This is the 
first time AREG and OSM have been shown to decrease OPG secretion from tumor cells, although a previous study 
demonstrated that AREG inhibits OPG secretion by osteoblasts, the primary source of this factor (54).  AREG is 
known to bind to the epidermal growth factor receptor (EGFR or ErbB1) for downstream signaling; however, a 
recent publication and our Western blot analysis indicate that 4T1.2 cells do not express this receptor (55).  With 
4T1.2 cells, it is possible that AREG binds an alternative receptor such as ErbB3/HER3 (56) to inhibit OPG 
expression.  OPG is associated with decreased osteoclastogenesis, and increased OPG expression in breast cancer 
cells has been shown to protect against osteolytic tumor growth in bone (57).  A proposed model summarizing our in 
vitro results is illustrated in Figure 7, in which OSM induces VEGF, IL-6, and AREG secretion from breast tumor 
cells.  Secreted VEGF and IL-6 bind to pre-osteoclasts to promote osteoclast differentiation, while AREG signals 
tumor cells to inhibit the production of the anti-osteoclastic factor OPG.   
 
In conclusion, this study demonstrates that tumor cell-derived OSM promotes osteolytic bone metastasis.  We 
propose this may be through a novel OSM-induced tumor-secreted factor AREG that leads to an increase in 
osteoclast activation by suppressing OPG.  Current therapies for osteolytic bone metastases, such as 
bisphosphonates, alleviate patient symptoms but have limited effect on inhibiting tumor cell metastasis to bone and 
relevant specific breast tumor-derived factors responsible for osteolysis.  Based on this study, we suggest that OSM 
could be a viable therapeutic target for patients with surgically removed primary tumors to reduce bone metastasis 
and prevent bone loss. 
 
Materials and Methods 
 
Cell lines and culture conditions 
 
66c14 and 4T1.2 cells were maintained in DMEM media supplemented with 10% fetal bovine serum (FBS), 1 mM 
sodium pyruvate, and 100 units/ml each of penicillin and streptomycin.  RAW 264.7 cells were obtained directly 
from the American Type Culture Collection (Rockville, MD), cultured in MEM media with the same supplements, 
and passaged for no more than 6 months.  Cells were maintained at 37 
o
C, 5% carbon dioxide, and 95% humidity.  
All media and supplements were obtained from Hyclone (Logan, UT).  66c14 and 4T1.2 mouse mammary cell lines 
were generated by the authors; therefore, there are no external lines against which they can be authenticated.   
 
Adherent Cell Count/Proliferation, Detachment, and Invasion Assays 
 
To assess the number of viable adherent cells correlating with proliferation, 1.0 x 10
3
 cells were seeded in 24-well 
plates with 1 ml of complete medium and treated with or without 25 ng/mL recombinant mouse OSM (R&D 
systems, Minneapolis, MN). Cells were detached using 0.25% trypsin (Hyclone) and counted using a 
hemocytometer every 2 days.  OSM-stimulated tumor cell detachment and invasion were conducted as described 
previously (20) with the following modifications to the invasion assay.  A total of 2.5 x 10
4
 cells were plated with or 
without 25 ng/mL OSM in the upper chamber of the Matrigel-coated invasion chambers (BD Biosciences, Bedford, 
MA) in normal growth medium without serum, and normal growth medium containing 10% FBS was added to the 
bottom chamber as a chemoattractant.  Staining of the invasion chambers was achieved with 0.05% crystal violet.  
Each Matrigel-coated or uncoated control membrane was counted in its entirety for each experiment.  Data for 
invasion assays is presented % invasion (# of cells that migrated through Matrigel-coated membranes/ # of cells that 
migrated through control membranes), according to manufacturer’s instructions.   
 
Enzyme Linked Immunosorbent Assay (ELISA) 
 
To measure OSM, AREG, and OPG in conditioned medium, a direct or sandwich ELISA was developed (see 
Supplemental Materials and Methods).  For the measurement of mouse VEGFA and mouse IL-6 in conditioned 
medium, ELISA kits (R&D systems) were utilized according to manufacturer’s instructions.  For all ELISAs, 1 x 
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10
5
 cells were plated per well in a 24-well plate in serum-free media and conditioned medium was collected 48 
hours later. 
 
Reverse-transcriptase PCR (RT-PCR) 
 
To determine the relative expression of various receptors in 4T1.2 and RAW 264.7 cells, RNA was extracted from 
these cells using RNA-STAT60 (Teltest, Friendswood, TX) according to manufacturer’s instructions, and RNA 
integrity was assessed using the bleach gel method as recently described (58).  cDNA was synthesized using 
GeneAmp RNA PCR kit (Applied Biosystems Carlsbad, CA) and amplified using the GoTaq PCR kit (Promega, 
Madison, WI).  Primer sequences and annealing temperatures (TA) are listed in Supplemental Table 1.  The 
thermocycler conditions for all PCR reactions were as follows:  95
o
C for 2 min, 29 cycles of 95
o
C for 1 min, TA for 
30 seconds, and 72
 o
C for 1 min and 72
 o
C for 1 min after the 29 cycles. Relative amount of RNA was quantified by 
densitometry of PCR products run on 0.5% agarose gels containing ethidium bromide. 
 
Plasmid construct design and cell transfections. 
 
To create OSM knockdown vectors, OSM  
shRNA sequences were cloned into the pSilencer 4.1 plasmid (Ambion, Austin, TX). A total of three shRNA 
constructs (1-3) were tested for OSM knockdown as well as a LacZ control using the same loop sequence of 
TTCAAGAGA and the following sense(s) and antisense(a) sequences:  OSM1s- 
GGACAGAGTCTTGTACCAACT, OSM1a- AGTTGGTACAAGACTCTGTCC; OSM2s- 
GTACCAACTGGATGCTTTA, OSM2a-TAAAGCATCCAGTTGGTACAA; OSM3s-
GCACAATATCCTCGGCATAAG, OSM3a-CTTATGCCGAGGATATTGTGC; LacZs-
GCTCCAAAGAAGAAGCGTT; LacZa-AACGCTTCTTCTTTGGAGC.  4T1.2 cells were transfected with the 
pSilencer 4.1 constructs containing the various mOSM shRNAs using lipofectamine LTX (Invitrogen Carlsbad, CA) 
reagent, as per manufacturer instructions. Stably transfected cell lines were grown in the presence of 0.3 mg/mL of 
the neomycin analogue G418 (Sigma Aldrich).  All established cell lines were checked for OSM expression by 
ELISA.   
 
Animals and Tumor Cell Injections 
 
Six-week-old female Balb/c mice were obtained from the National Cancer Institute’s Animal Production Facility 
(Frederick, MD).  For orthotopic injections, each mouse was anesthetized by i.p. injection of 6.25 mg/kg of sodium 
pentobarbital or with 2.5% isoflurane and 1.0x10
5 
cells diluted in 10 L of PBS containing 10% medium were 
injected into the 4
th
 mammary fat pad.  For intratibial injections, 1 x 10
4 
cells in 30 l PBS containing 10% medium 
were injected and needle placement was verified by X-ray as previously described (59).  For tumor resection, 
mammary tumors were surgically excised 14 days after orthotopic injections.  All animal studies were conducted in 
accordance with the protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the Boise 
VA Medical Center, Washington University School of Medicine in St. Louis, MO, or the Peter MacCallum Cancer 
Centre in Melbourne, Australia.  Starting at 2 weeks post-injection, tumor length and width were measured by 
mechanical calipers 3 times a week and tumor volume was extrapolated using the following equation (tumor volume 
= (length x width
2) /2).  “Survival endpoint” was defined by the IACUC as tumor size greater than 20 mm in 
diameter, 10% or more weight loss, and/or appearance of cachexia.  
 
Quantitative PCR (qPCR) 
 
Spines dissected from mice bearing mammary tumors were stripped of any soft tissue, snap-frozen in liquid 
nitrogen, and pulverized into a fine powder.  DNA was extracted using an STE buffer containing 20 μl/ml of 
proteinase K and purified by two phenol/chloroform (1:1 v/v) extractions followed by ethanol precipitation.  The 
ratio of cancer cells to normal cells was quantified by measuring genomic DNA levels for the neomycin resistance 
gene (neo
r
) found integrated in tumor cells versus the DNA levels for a control gene vimentin present in all cells, as 
described previously (60).  Taqman PCR was performed on an Applied Biosystems 7500 real-time thermocycler.  
Probe and primer sequences are listed in Supplemental Table 1. The cycling conditions were run as follows: 50
 o
C 
for 5 minutes, 95
 o
C for 2 minutes, then 40 cycles of 95
 o
C for 1 minutes and 60
 o
C for 45 seconds.  Fluorescence 
was measured every cycle after the annealing step and threshold cycle number (Ct) values were calculated. The data 
was analyzed using the comparative Ct method (61). 
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Histology 
 
To verify the location of spine metastasis, spines from each experimental group (4T1.2-LacZ, n=2; 4T1.2-OSM2, 
n=2; and 4T1.2-OSM1, n=1) were placed in ultralight fixative (Ultralight Histology, Nampa, ID) paraffin 
embedded, and sectioned (Bi-Biomics, Nampa, ID).  For each spine, four 1 m sections were collected 10 m apart 
in the lumbar region and H&E stained.   
 
Micro-computed tomography (Micro CT) Analysis of In Vivo Osteolysis 
 
For determining the 3-D architecture of the trabecular and cortical bone, mice were euthanized and the hind limb 
was removed and placed in 10% formalin overnight before being transferred to 70% ethanol for analysis using a 
vivaCT40 scanner (Scanco Medical AG, Switzerland).  Tube settings were at 55 kVp and 145 μA with a tube 
diameter of 21.5 mm. The entire hind limb (femur, tibia, and fibula) was scanned at a 10 μm isometric resolution 
with 250 ms integration time.  For trabecular bone analysis, the end of the growth plate was used as the landmark 
and a 0.525 mm (50 slices) region below the landmark (metaphysis) was considered as the region of interest 
(ROI).  Contours were drawn on 50 slices distal to the landmark around the trabecular bone only (endo-cortical 
boundary).  An additional analysis of the cortical bone below the growth plate was performed from the trabecular 
bone analysis scans.  The mid-diaphyseal region (approximate middle of the proximal-end and tibia-fibula junction) 
of the tibia was considered as the ROI for cortical bone analysis. Two contours were drawn on 50 slices of the ROI; 
one at the periosteal surface (inclusive) including the cortical bone and other at the endosteal surface of the bone 
(exclusive) to exclude the medullary region.  A Gaussian filter (with Gaussian sigma of 0.4, and Support of 1) was 
applied on all slices before image segmentation. All the contoured slices were segmented and analyzed with the 
global threshold value of 250 'per-mille’ (Linear attenuation coefficient (μ) of 2.00 [1/cm]).  
 
Osteoclastogenesis Assay 
 
1.0 x 10
4
 RAW 264.7 cells were added to each well of a 24-well plate in duplicate in complete MEM medium 
containing 50mg/L L-ascorbic acid. 1.0 x 10
3
 4T1.2 cells were plated in co-culture with the RAW 264.7 cells or 
alone and 25 ng/ml OSM and/or 50 ng/ml AREG were added. All osteoclastogenesis assays included very low 
levels of RANKL and MCSF (10 ng/ml RANKL and 5 ng/ml of MCSF). Two hours before the addition of OSM, 
AREG, VEGF, and IL-6 neutralizing antibodies were added at final concentration of 1 g/ml where indicated.  All 
mouse factors and antibodies were obtained from R&D Systems Minneapolis, MN.  The co-cultures were 
maintained for 9-10 days without any changes of the medium and osteoclasts were stained using a tartrate resistant 
acid phosphate (TRAP) stain kit (Sigma Aldrich St. Louis, MO) according to manufacturer’s instructions.  TRAP-
positive cells that stained purple were counted and quantified per well. 
 
Statistical Analysis 
 
Data are displayed as mean  standard error of the mean (SEM).  Data were analyzed using an unpaired student’s t-
test or analysis of variance (ANOVA) with Tukey’s multiple comparison post-hoc test where appropriate, using 
Prism GraphPad 5.0b software (GraphPad Software Inc., San Diego, CA).  Survival data were analyzed using the 
Log-rank (Mantel-Cox) test. Asterisks denote *p<0.05, **p<0.01, or ***p<0.001.   
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FIGURE LEGENDS 
 
Figure 1. 
OSM-induced invasive potential of mouse mammary tumor cells in vitro.  A, Secreted OSM 
levels (ELISA) from equal numbers of cells (1x10
5
) and B, semi-quantitative expression of 
OSMR (RT-PCR, normalized to GAPDH expression) was compared between 66c14 and 4T1.2 
mouse mammary tumor cells.  C, Bone metastatic mammary tumor 4T1.2 cells were treated with 
25 ng/ml OSM and show decreased adherent cell number over time (left) and increased cell 
detachment (right) when monitored for up to 10 days in culture.  D, The percentage of 4T1.2 
cells that migrated through Matrigel-coated transwell plates increased with 24-hour OSM 
treatment.  Single chambers from 3 independent experiments were analyzed; data expressed as 
mean  SEM, *P < 0.05, t-test. 
 
Figure 2. 
4T1.2 cells with reduced OSM expression are less metastatic to bone.  A, 4T1.2 cells were 
transfected with shRNAs directed against the control LacZ or OSM (sequences 1-2), and 
secreted OSM was measured by ELISA in medium collected from wells containing 1 x 10
5
 cells 
as well as RT-PCR (inset).  B, Control 4T1.2-LacZ, 4T1.2-OSM1, or 4T1.2-OSM2 cells were 
injected into the 4
th
 mammary fat pad of female Balb/c mice and tumor growth was measured.  
Average tumor volume (mm
3
) in control 4T1.2-LacZ, 4T1.2-OSM1, and 4T1.2-OSM2 cell-
injected mice was monitored and significantly increased in 4T1.2-OSM2 mice at 30 days post-
tumor cell injection compared to controls.    C, 4T1.2-OSM1 and 4T1.2-OSM2, compared to 
control 4T1.2-LacZ injected mice, have significantly reduced spontaneous bone metastases as 
assessed by qPCR.  D, Representative histology (H & E stain) shows a large intraosseous 
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metastasis in the vertebral pedicle of a 4T1.2-LacZ spine (n=2), a single small metastasis in the 
outside edge of the vertebral body of a 4T1.2-OSM1 spine, and only normal osseous tissue in 
4T1.2-OSM2 spine (n=2).  (4T1.2-LacZ, n=22; 4T1.2-OSM1, n=14; 4T1.2-OSM2, n=22).  Data 
expressed as mean  SEM, *P < 0.05; (A) One-way ANOVA with Tukey’s post-hoc test, (B and 
D) t-test.  
 
Figure 3. 
Reduced OSM expression by 4T1.2 cells protects against bone osteolysis.  A, Representative 
3D reconstructions of hind limbs were generated from Micro CT scans performed 4 weeks after 
intratibial injection of PBS, control 4T1.2-LacZ cells, or 4T1.2-OSM2 cells.  Insets show 
extensive osteolysis in the proximal tibia of mice injected with control cells.  B, ROI 3D 
reconstructions of trabecular (top) and cortical bone (bottom) show less osteolytic degradation 
in tibias injected with 4T1.2-OSM2 cells compared to control cells.  C, Quantitative analyses 
were performed for total trabecular volume, total trabecular thickness, cortical bone volume/total 
volume, and cortical bone mineral density.  (PBS, n=2; 4T1.2-LacZ, n=3; 4T1.2-OSM2, n=4).  
Data expressed as mean  SEM.  *P<0.001, t-test 4T1.2-OSM2 vs 4T1.2-LacZ.  BDL (below 
detection limit) is presented when no data could be obtained and resulted in the inability to 
perform statistics. 
 
Figure 4. 
Reduced OSM expression by 4T1.2 tumors increases survival.  A, The timeline shows 
orthotopic mammary tumor cell injection at day 0, resection at day 14, and final day of sacrifice 
per group.  B, Kaplan-Meier analysis of survival following tumor resection shows a significant 
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increase in survival in mice injected with 4T1.2-OSM2 cells. C, Relative metastatic burden for 
spine was also significantly lower in the 4T1.2-OSM2 injected mice as assessed by qPCR. 
(4T1.2-LacZ, n=6; 4T1.2-OSM2, n=10).  Data expressed as mean  SEM.  **P<0.01, Log-rank 
test, ***P<0.001, t-test.   
 
Figure 5 
OSM induces 4T1.2 tumor cell-mediated osteoclastogenesis in vitro.  A, Expression of 
various receptors on mouse 4T1.2 and RAW 264.7 cells was analyzed by RT-PCR (normalized 
to GAPDH expression).  B, 10-day treatment with 25 ng/ml of OSM increases the number of 
TRAP+ cells in RAW 264.7 and 4T1.2 cell co-cultures and RAW 264.7 cells treated with 4T1.2 
cell CM.  C, OSM induces IL-6 and D, VEGF secretion in 4T1.2 cells and co-cultures of RAW 
264.7 and 4T1.2 cells, measured by ELISA (total of 1 x 10
5
 cells per well).  *P < 0.05; 
***P<0.001, Two-way ANOVA with Boneferroni post-hoc test. 
 
Figure 6. 
OSM-induced AREG secretion drives 4T1.2 cell-mediated osteoclastogenesis in vitro.  A, 
The amount of AREG secreted by 4T1.2 cells, co-cultures of 4T1.2 and RAW 264.7 cells, or 
RAW 264.7 cells alone (total of 1 x 10
5
 cells) increases after 48-hour treatment with 25 ng/ml 
OSM, as analyzed by ELISA (left). 10-day recombinant AREG (50 ng/ml) and OSM (25 ng/ml) 
treatment increases the number of TRAP+ cells in co-cultures of RAW 264.7 and 4T1.2 cells 
(right).  B, Addition of a neutralizing antibody against AREG (1 g/ml anti-AREG) 2 hours 
prior to OSM treatment blocks the increase in the number of OSM-induced TRAP+ cells (left).  
A comparison of the percent increase in TRAP+ cells (% of -OSM Control) in co-cultures of 
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RAW 264.7 and 4T1.2 cells treated with neutralizing antibodies directed against IL-6 (anti-IL-6, 
1 g/ml), VEGF (anti-VEGF, 1 g/ml), and anti-AREG (1 g/ml) 2 hours prior to the addition of 
OSM is shown (right).  C, OSM inhibits OPG secretion levels, as assessed by ELISA (left).  
OSM and AREG inhibit OPG mRNA expression by RT-PCR (normalized to GAPDH) (right).  
*P < 0.05, ***P<0.001; Two-way ANOVA with Boneferroni post-hoc analysis (A and B, 
left);***P<0.05, **P<0.01, ***P<0.001; One-way ANOVA with Tukey's post-hoc analysis (B, 
right, + OSM groups); *P < 0.05; Unpaired t-test (C). 
 
Figure 7. 
Proposed model for the mechanism of OSM in tumor cell-mediated osteoclastogenesis.  
OSM increases VEGF and IL-6 secretion from tumor cells that then bind to pre-osteoclasts and 
mature osteoclasts on their respective VEGF and IL-6 receptors (VEGFR and IL-6R) to promote 
osteoclastogenesis and osteoclast activity in the presence of RANKL and M-CSF, resulting in 
bone resorption.  OSM also induces tumor cell-secreted AREG that signals via an unknown 
receptor to suppress OPG production and reduce its ability to bind RANKL and inhibit 
osteoclastogenesis.  Thus membrane-bound RANKL on osteoblasts or soluble RANKL 
(sRANKL) is more available to bind to RANK on pre-osteoclasts, thereby promoting 
osteoclastogenesis.  cFMS; receptor for M-CSF. 
17
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
 
18
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
 
19
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
20
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
21
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
22
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
23
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
 
24
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
25
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
26
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
27
   
This document was originally published by SAGE in Genes & Cancer.  Copyright restrictions may apply.  
DOI: 10.1177/1947601912458284 
 
 
28
